Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A.

Core Viewpoint - Aquestive Therapeutics, Inc. has appointed Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, succeeding Lori J. Braender, who will remain as Corporate Secretary [1][5] Company Leadership Changes - Thomas A. Zalewski brings extensive experience in life sciences law and has previously served as a Partner and Chair of the Healthcare and Life Sciences practice at Day Pitney LLP [1][2] - Lori J. Braender has served as Chief Legal Officer and Chief Compliance Officer since September 2018 and will continue as Corporate Secretary after her transition [3][5] Compensation and Inducement - Mr. Zalewski will receive an equity award of 100,000 Restricted Stock Units and 75,000 non-qualified common stock options as part of his inducement to join the company [4] - The equity awards will vest over three years, with 25% vesting after the first and second anniversaries, and 50% on the third anniversary [4] Company Overview - Aquestive Therapeutics is focused on advancing medicines through innovative science and delivery technologies, operating as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) [6] - The company is known for its PharmFilm® technology and is advancing Anaphylm™, the first oral epinephrine rescue medication, towards FDA approval [6]